Quantcast

Latest Capecitabine Stories

2010-01-21 07:30:00

NEW YORK, Jan 21 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that updated results from its Phase 2 clinical trial of KRX-0401 (perifosine) in combination with capecitabine has been selected for poster presentation at the upcoming ASCO 2010 Gastrointestinal Cancers Symposium, to be held in Orlando, Florida from January 22-24, 2010. The clinical data to be presented demonstrates the potential safety and efficacy of KRX-0401 in the treatment of...

2009-12-11 15:45:00

WAYNE, N.J. and EMERYVILLE, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS). The first of these studies evaluated Nexavar® (sorafenib) tablets in combination with chemotherapy agent capecitabine and the...

2009-12-11 12:30:00

LONDON and PHILADELPHIA, Dec. 11 /PRNewswire/ -- In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9...

2009-11-11 02:00:00

Finland, November 11 /PRNewswire/ -- - This is a third party press release. It will be issued by the Finnish Breast Cancer Group on Wednesday 11 November 2009. - FinXX, a Large, Phase III Randomised Study in Women With Early Breast Cancer Shows that Adding Capecitabine (Xeloda(R)) to a Treatment Regimen Containing Standard Agents Allows More Women to Live Cancer-Free for Longer An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology...

2009-11-03 09:58:00

NEW YORK, Nov. 3 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Chinese Markets for Colon Cancer Treatment Drugs http://www.reportlinker.com/p0157398/Chinese-Markets-for-Colon-Cancer-Treatment-Drugs.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire China's demand for Colon Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue...

2009-09-30 01:00:00

WAYNE, N.J. and EMERYVILLE, Calif., Sept. 30 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from a randomized, placebo-controlled Phase 2 trial sponsored by Northwestern University. The study, which evaluated Nexavar® (sorafenib) tablets in combination with the chemotherapeutic agent, paclitaxel, in patients with locally advanced or metastatic HER-2 negative breast cancer, demonstrated a...

2009-09-23 05:30:00

BERLIN, Sept. 23 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer. The data were presented at the...

2009-09-23 06:15:00

BERLIN, September 23 /PRNewswire/ -- - The Austrian Breast and Colorectal Cancer Study Group Present Data Which Highlight Benefits of Adding capecitabine to epirubicin and docetaxel in the Neoadjuvant Setting Data from the ABCSG-24 study presented today at the joint 15th ECCO and 34th ESMO congress in Berlin, Germany, show that adding capecitabine (Xeloda(R)) to anthracycline- and taxane-containing regimens prior to surgery (neoadjuvant therapy) completely eradicated the tumour...

2009-09-23 08:17:37

Results from first, large randomized trial One of the first of a series of trials to investigate the use of sorafenib "“ a targeted anti-cancer drug "“ for the treatment of advanced breast cancer has found that if it is combined with the chemotherapy drug, capecitabine, it makes a significant difference to the time women live without their disease worsening. Principal investigator of the study, Professor Jos© Baselga told Europe's largest cancer congress, ECCO 15 "“...

2009-07-22 07:00:00

WAYNE, N.J. and EMERYVILLE, Calif., July 22 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that their first cooperative group-sponsored randomized Phase 2 trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related